FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

Read Full Article from CURE TODAY

FDA approval of Tepylute provides a ready-to-dilute thiotepa formulation for breast and ovarian cancer treatment, enhancing convenience and reducing preparation errors.

The new formulation eliminates the need for reconstitution, saving time and offering more scheduling flexibility for healthcare providers.

LATEST NEWS